Actively Recruiting

Age: 35Years +
All Genders
NCT06188065

Eosinopenia in Severe COPD Exacerbation

Led by Northumbria Healthcare NHS Foundation Trust · Updated on 2026-04-14

200

Participants Needed

1

Research Sites

127 weeks

Total Duration

On this page

Sponsors

N

Northumbria Healthcare NHS Foundation Trust

Lead Sponsor

N

Newcastle University

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) and to determine when blood eosinophil count (BEC) will recover to baseline stable state in patients who are admitted to hospital with a severe exacerbation of COPD and associated eosinopenia. The main aims of the study are to: 1. Identify demographic, physiological and clinical factors independently associated with admission eosinopenia in patients with a severe exacerbation of COPD 2. Assess the time to recovery from eosinopenia to stable BEC following a severe exacerbation of COPD

CONDITIONS

Official Title

Eosinopenia in Severe COPD Exacerbation

Who Can Participate

Age: 35Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Admitted to hospital with primary clinical diagnosis of exacerbation of COPD
  • Smoking history of at least 10 pack years
  • Airflow obstruction: FEV1/FVC ratio < 0.7 confirmed on historic or inpatient spirometry
  • Capacity to give informed consent to participate
  • Eosinopenia on admission (for time to recovery analysis)
  • Uneventful recovery: no further systemic corticosteroids or emergency hospital admissions within six weeks following COPD exacerbation (for time to recovery analysis)
Not Eligible

You will not qualify if you...

  • Parasitic infection, systemic fungal infection (excluding nails or skin), eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or other conditions causing high eosinophil count
  • Active malignancy
  • Maintenance oral prednisolone or other systemic steroids, anti-interleukin 5 therapy, or other medications affecting eosinophils
  • Poor venous access
  • Investigator-confirmed history of asthma
  • Non-COPD health problems that may interfere with study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Northumbria Healthcare NHS Foundation Trust

North Shields, United Kingdom

Actively Recruiting

Loading map...

Research Team

S

Stephen Bourke, MBChB, PhD

CONTACT

P

Peter Ireland, MBBS

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here